期刊文献+

达沙替尼治疗伊马替尼引起肝功能异常的慢性粒细胞白血病1例报告 被引量:3

Dasatinib tablets in treating chronic myelocytic leukemia patient with imatinib-induced hepatic dysfunction:a case report
下载PDF
导出
摘要 1病例资料患者,女,60岁,2013年2月诊断为慢性粒细胞白血病(chronic myelocytic leukemia,CML),间断应用羟基脲治疗。2014年4月20日,因"乏力、纳差、腹胀"入院治疗,入院时查血常规,白细胞(WBC)计数121×10~9/L,血红蛋白(Hb)浓度10~3 g/L,血小板(PLT)计数708×10~9/L。
出处 《第二军医大学学报》 CAS CSCD 北大核心 2016年第1期129-130,共2页 Academic Journal of Second Military Medical University
关键词 达沙替尼 慢性粒细胞白血病 酪氨酸激酶抑制剂 dasatinib~ chronic myelocytic leukemia tyrosine kinase inhibitor
  • 相关文献

参考文献10

二级参考文献80

  • 1吴洪斌,陆益,陆国椿.甲磺酸伊马替尼的不良反应及预防处理[J].中国新药杂志,2006,15(22):1923-1925. 被引量:18
  • 2陈燕华.甲磺酸伊马替尼致黄疸[J].药物不良反应杂志,2007,9(2):141-142. 被引量:6
  • 3O' BRIEN S G, GUILHOT F, LARSON R A, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J]. N Engl J Med, 2003,348 : 994-- 1004.
  • 4HOCHHAUS A, O' BRIEN S G, GUILHOT F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia[J]. Leukemia, 2009,23 : 1054-- 1061.
  • 5SHAH N P,NICOLL J M,NAGAR B,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia[J]. Cancer Cell, 2002,2 .. 117 -- 125.
  • 6KANTARJIAN H M, GILES F, BHALLA K N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results[J]. Blood,2011,117:1141--1145.
  • 7GILES F J,LARSON R A,KANTARJIAN H M,et al. Nilotinib in chronic myelogenous leukemia in blast crisis (CML-BC) patients with imatinib-resistance or -intolerance.. updated phase 2 results[J]. Haematolog- ica,2008,93(Suppl. 1) :abstract 0117.
  • 8HOCHHAUSA, GILES F, APPERLEY J, et al. Nilotinib in chronic myeloid leukemia in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study[J]. Haematologica, 2009,94 (Suppl. 2) .. abstract 0631.
  • 9LE COUTRE P, OTTMANN O G, GILES F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia[J]. Blood, 2008,111 ; 1834-- 1839.
  • 10O' BRIEN S G, GUILHOT F, GOLDMAN J M, et al. International randomized study of interferon ver sus STI571 (IRIS) 7-year follow up: Sustained sur viral,low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [J]. Blood (ASH Annual Meeting Abstracts), 2008, 112:186--186.

共引文献30

同被引文献23

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部